Cerebral Vasospasm Market Research Report Information, By Diagnosis (Comoted Tomography Angiography, Digital Subtraction Angiography, Magnetic Resonance Angiography, and Transcranial Doppler), By Treatment (Nimodipine, Triple-H Therapy, Balloon Angioplasty, Vasopressors, Inotropes, Thrombolytic Agents, Anti-Inflammatory Agents), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Trauma Centers, Emergency Departments, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Cerebral Vasospasm Market Overview

Cerebral Vasospasm Market Size was valued at USD 2.1 Billion in 2022. The Cerebral Vasospasm market industry is projected to grow from USD 2.25 Billion in 2023 to USD 3.95 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.30% during the forecast period (2023 - 2032). Rising smoking habits among youths and increasing instances of traumatic brain injury are the prime market drivers helping the market to grow.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Cerebral Vasospasm Market Trends

• Growing traumatic brain injuries is driving the market growth

The Market CAGR for cerebral vasospasm is expanding at an accelerated rate because of the rise in traumatic brain injuries. Vasospasm of the cerebral arteries is referred to as cerebral. Patients who recover from subarachnoid haemorrhage frequently experience it. Ischemia of the brain and mortality follow the situation of cerebral artery constriction.

The occurrence of subarachnoid haemorrhage among people worldwide is rising, which is accelerating the market growth for cerebral vasospasm. The expansion of the cerebral vasospasm market is accelerated by the increase in cases of traumatic brain injury, bleeding problems, and unhealthy lifestyles including smoking and drinking. The market for cerebral vasospasm is also impacted by the rise in accidents among people, particularly the ageing population, and the rising usage of blood thinners. Additionally, the market for cerebral vasospasm is favourably impacted by the rise in hypertension among the populace, expanding elderly population, increase in awareness, acceptance of sophisticated technologies, rise in healthcare spending, increase in research and development activities, and spike in investments. Thus, driving the Cerebral Vasospasm market revenue.

Further, COVID-19 may result in issues with the respiratory system in addition to other primary and secondary nervous system issues. Patients with COVID-19 have reported experiencing acute cerebral vasospasm symptoms like sudden speech stuttering and limb paralysis, intracranial infection symptoms like headache, epilepsy, and alterations in consciousness, muscle damage symptoms like soreness and weakness of the limbs, and sporadically symptoms like neuralgia, an abnormal sensation. Neurologists should pay special attention to this patient population during this period of high COVID-19 prevalence, especially those with nervous system symptoms. The Cerebral Vasospasm Market Trends may be halted by COVID-19.

Cerebral Vasospasm Market Segment Insights

Cerebral Vasospasm Form Insights

The Cerebral Vasospasm market segmentation, based on diagnosis includes Comoted tomography angiography, Digital subtraction Angiography, Magnetic Resonance Angiography, and Transcranial Doppler. The comoted tomography angiography segment dominated the market. For subarachnoid haemorrhage patients with delayed cerebral ischemia, computed tomography angiography (CTA) and computed tomography perfusion imaging (CTP) are routinely used to assess whether endovascular vasospasm therapy is necessary.

Cerebral Vasospasm Treatment Insights

The Cerebral Vasospasm market segmentation, based on treatment, includes Nimodipine, Triple-H Therapy, Balloon Angioplasty, Vasopressors, Inotropes, Thrombolytic Agents, and Anti-Inflammatory Agents. The nimodipine category generated the most income. By blocking the voltage-operated calcium channels, the calcium antagonist nimodipine lowers the calcium influx in smooth muscle cells. This could result in lessened vascular smooth muscle contraction and lessened endothelial and platelet production of vasoactive chemicals. Numerous trials (15–18) have demonstrated the effectiveness of preventive oral or intravenous nimodipine in lowering the signs of cerebral infarction and enhancing recovery from SAH.  

Cerebral Vasospasm End User Insights

The Cerebral Vasospasm market segmentation, based on end user, includes Hospitals, Clinics, Ambulatory surgical centers, Trauma Centers, Emergency Departments, and Others. The trauma centers generated the most income. The segment's growth is accelerating due to the rise in traumatic brain injuries. The occurrence of subarachnoid hemorrhage among people worldwide is rising, which is accelerating the segment's growth. The segmental expansion is accelerated by the increase of traumatic brain injury and bleeding disorders cases, as well as the adoption of poor lifestyle choices like drinking and smoking.

Figure 1 Cerebral Vasospasm Market, by End User, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Cerebral Vasospasm Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Cerebral Vasospasm market area will dominate this market, owing to an increasing number of brain traumatic injuries and increasing expenditures over healthcare industry.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 CEREBRAL VASOSPASM MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Cerebral Vasospasm market accounts for the second-largest market share due to the growing smoking habits among the people of the region. Further, the German Cerebral Vasospasm market held the largest market share, and the UK Cerebral Vasospasm market was among the fastest-growing market in the European region

The Asia-Pacific Cerebral Vasospasm Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to growing count of old aged people. Moreover, China’s Cerebral Vasospasm market held the largest market share, and the Indian Cerebral Vasospasm market was among the fastest-growing market in the Asia-Pacific region.

Cerebral Vasospasm Key Market Players & Competitive Insights

Leading market players are expanding and widening their product offerings, to acquire more competitive position in the market, which will lead the Cerebral Vasospasm market, even faster. Market participants are also adopting a variety of strategic activities to acquire leading position, with important market developments tactics including new product developments & upgrades, contractual agreements, mergers & acquisitions, collaborations, higher investments, and collaboration with other organizations. To grow and survive in a competitive and rising market climate, Cerebral Vasospasm industry must provide cost-effective items.

The manufacturers are laying emphasis on the use of local resources to achieve operational efficiency in the Cerebral Vasospasm industry to benefit clients and increase the market sector. In recent years, the Cerebral Vasospasm industry has offered some of the most significant benefits to medicine. Major players in the Cerebral Vasospasm market, including Headsense Medical Ltd., B. Braun Melsungen, Minnetronix, Bristol-Myers Squibb Company, Ingehlium GmbH, H. Lundbeck A/S, Actellion Pharmaceuticals Ltd., GE Healthcare, Edge Therapeutics Inc., Siemens AG, Aritria Medical, Philips N.V., and others, are attempting to increase market demand by investing in research and development operations.

Siemens AG (Siemens) is a technology-based company. Its operations cut across the sectors of electrification, automation, and digitalization. The business develops, produces, and installs items as well as sophisticated systems and projects. Additionally, a vast array of specially designed solutions are offered for different needs. Siemens focuses on energy production and delivery, as well as intelligent building infrastructure and distributed energy systems. It offers medical technology, digital healthcare services, and smart mobility solutions for both transportation i.e., rail and road. Worldwide, Siemens has a network of production facilities, warehouses, and sales offices. It offers services to customers in a range of sectors, including energy, healthcare, infrastructure, process and manufacturing, among others. In Germany's Bavaria region, Munich serves as the home of Siemens. In July 2022, The ARTIS iconi ceiling, a ceiling-mounted angiography system developed for a range of standard and cutting-edge procedures in interventional radiology (IR) and cardiology, has received FDA certification, according to Siemens Healthineers. The system is developed for a combination of surgical operations because of its considerable mechanical flexibility.

Minnetronix a company that offers manufacturing, product development, and design services to the medical technology sector. By accelerating the delivery of medical products and life-saving treatments, the company, which specializes in developing a variety of proprietary platform technologies, hopes to address the unmet needs of clients, clinicians, and patients. These technologies include stimulation systems, ventricular assist devices, thrombectomy, ultrasound, blood pumping, and vacuum pumping systems. In February 2021, A majority recapitalization with Altaris Capital Partners, LLC was announced today by Minnetronix Medical, Inc., a leading provider of medical technology and an operating partner to numerous international medical device firms. Altaris, an investment company with a healthcare sector concentration, has been a minority shareholder in Minnetronix since 2015 and actively manages $4.9 billion in equity capital.

Key Companies in the Cerebral Vasospasm market include

• Headsense Medical Ltd.,


• Braun Melsungen,


• Minnetronix,


• Bristol-Myers Squibb Company,


• Ingehlium GmbH,


• Lundbeck A/S,


• Actellion Pharmaceuticals Ltd.,


• GE Healthcare,


• Edge Therapeutics Inc.,


• Siemens AG,


• Aritria Medical,


• Philips N.V.,

Cerebral Vasospasm Industry Developments

July 2022 An expert consensus document on Coronary Artery Disease - Reporting and Data System (CAD-RADS) has been published by the Society of Cardiovascular Computed Tomography (SCCT) in association with the American College of Cardiology (ACC), the American College of Radiology (ACR), and the North America Society of Cardiovascular Imaging (NASCI).

August 2022 In order to solve the existing iodinated contrast media scarcity, Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has allowed import discretion of Iomeron (iomeprol injectable) into the U.S. The device, which would have been momentarily accessible on the American market beginning at the end of August 2022, satisfies the requirement for the most cutting-edge diagnostic imaging standards.

July 2021 For Joel (J.G.) Fletcher, M.D., and Cynthia McCollough, Ph.D., performing the initial heart scan on their brand-new photon-counting detector computed tomography (CT) scanner was a once-in-a-career experience. The arrival of this newest research CT system is a significant milestone in CT imaging, one where Mayo Clinic is once again at the vanguard, according to the medical and scientific directors, respectively, of the CT Clinical Innovation Centre.

Cerebral Vasospasm Market Segmentation

Cerebral Vasospasm Diagnosis Outlook (USD Billion, 2018-2032)

• Comoted tomography angiography


• Digital subtraction Angiography


• 
  Magnetic Resonance Angiography,


• Transcranial Doppler

Cerebral Vasospasm Treatment Outlook (USD Billion, 2018-2032)

• Nimodipine


• Triple-H Therapy


• Balloon Angioplasty


• Vasopressors,


• Inotropes,


• Thrombolytic Agents,


• Anti-Inflammatory Agents

Cerebral Vasospasm End User Outlook (USD Billion, 2018-2032)

• Hospitals


• Clinics


• Ambulatory surgical centers,


• Trauma Centers,


• Emergency Departments,


• Others

Cerebral Vasospasm Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America